Hexagon Capital Partners LLC Has $678,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Hexagon Capital Partners LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGNGet Rating) by 3.2% in the first quarter, HoldingsChannel reports. The fund owned 2,805 shares of the medical research company’s stock after buying an additional 88 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Amgen were worth $678,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Norges Bank purchased a new position in Amgen in the fourth quarter valued at about $1,138,930,000. BlackRock Inc. lifted its holdings in shares of Amgen by 2.1% during the 4th quarter. BlackRock Inc. now owns 50,046,345 shares of the medical research company’s stock valued at $11,258,926,000 after buying an additional 1,032,929 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Amgen by 625.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,101,853 shares of the medical research company’s stock valued at $247,884,000 after buying an additional 950,008 shares in the last quarter. First Trust Advisors LP increased its holdings in Amgen by 125.5% in the fourth quarter. First Trust Advisors LP now owns 1,613,704 shares of the medical research company’s stock worth $363,035,000 after buying an additional 898,059 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Amgen by 6.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,725,125 shares of the medical research company’s stock valued at $1,962,892,000 after acquiring an additional 561,955 shares in the last quarter. 79.01% of the stock is currently owned by institutional investors.

In other Amgen news, EVP Jonathan P. Graham sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $241.81, for a total transaction of $3,264,435.00. Following the transaction, the executive vice president now owns 37,333 shares of the company’s stock, valued at approximately $9,027,492.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director R Sanders Williams sold 600 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $250.00, for a total value of $150,000.00. Following the completion of the sale, the director now directly owns 5,501 shares of the company’s stock, valued at approximately $1,375,250. The disclosure for this sale can be found here. 0.46% of the stock is owned by corporate insiders.

A number of equities analysts have recently commented on the stock. BMO Capital Markets dropped their price target on shares of Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Monday, May 16th. Barclays increased their price target on shares of Amgen from $233.00 to $236.00 and gave the company an “equal weight” rating in a report on Tuesday, April 12th. Piper Sandler boosted their price objective on shares of Amgen from $255.00 to $260.00 in a report on Thursday, April 28th. Finally, SVB Leerink started coverage on Amgen in a research note on Monday, May 23rd. They set a “market perform” rating and a $256.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $242.57.

Shares of Amgen stock opened at $240.14 on Thursday. The business has a fifty day simple moving average of $244.62 and a 200 day simple moving average of $234.69. The stock has a market cap of $128.28 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.09, a current ratio of 1.44 and a debt-to-equity ratio of 39.31. Amgen Inc. has a 12 month low of $198.64 and a 12 month high of $258.45.

Amgen (NASDAQ:AMGNGet Rating) last posted its earnings results on Wednesday, April 27th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.22 by $0.03. The company had revenue of $6.24 billion during the quarter, compared to analyst estimates of $6.09 billion. Amgen had a return on equity of 165.95% and a net margin of 21.75%. During the same period in the previous year, the company earned $3.70 EPS. Analysts expect that Amgen Inc. will post 17.44 EPS for the current fiscal year.

Amgen Company Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNGet Rating).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.